Sharadah Essapen
A5047381801- Colorectal Cancer Treatments and Studies
- Ovarian cancer diagnosis and treatment
- HER2/EGFR in Cancer Research
- Colorectal Cancer Surgical Treatments
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Intraperitoneal and Appendiceal Malignancies
- Cancer Treatment and Pharmacology
- Colorectal and Anal Carcinomas
- Endometrial and Cervical Cancer Treatments
- Advanced Radiotherapy Techniques
- Genetic factors in colorectal cancer
- Cancer Research and Treatments
- Advances in Oncology and Radiotherapy
- Cancer Mechanisms and Therapy
- Radiomics and Machine Learning in Medical Imaging
- Cancer Cells and Metastasis
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Pancreatic and Hepatic Oncology Research
- Angiogenesis and VEGF in Cancer
- Metastasis and carcinoma case studies
- Glycosylation and Glycoproteins Research
- Hepatocellular Carcinoma Treatment and Prognosis
Royal Surrey County Hospital
2013-2023
Kingston University
2014-2021
Royal Surrey NHS Foundation Trust
2012-2021
University of Birmingham
2020
University of Amsterdam
2020
Amsterdam UMC Location University of Amsterdam
2020
Chesterfield Royal Hospital NHS Foundation Trust
2020
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
2020
Dorset County Hospital NHS Foundation Trust
2020
East Kent Hospitals University NHS Foundation Trust
2020
Angiogenesis plays a role in the biology of ovarian cancer. We examined effect bevacizumab, vascular endothelial growth factor inhibitor, on survival women with this disease.
BackgroundThe interim analysis of the multicentre New EPOC trial in patients with resectable colorectal liver metastasis showed a significant reduction progression-free survival allocated to cetuximab plus chemotherapy compared those given alone. The focus present was assess effect on overall survival.MethodsNew multicentre, open-label, randomised, controlled, phase 3 trial. Adult (aged ≥18 years) KRAS wild-type (codons 12, 13, and 61) or suboptimally metastases WHO performance status 0–2...
BackgroundRadical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective could reduce adverse effects of without substantially compromising oncological outcomes. We investigated feasibility recruiting patients to a randomised trial comparing an excision.MethodsTREC was randomised, open-label study done at 21 tertiary referral centres in UK. Eligible participants were aged 18 years or older...
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether would be non-inferior to the usual treatment.The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk II and III cancer underwent central randomisation minimisation centre, choice regimen, sex, disease site, N stage, T starting dose capecitabine. were assigned...
5500 Background: First line treatment of advanced ovarian cancer (OC) is accepted to be primary surgery (PS) followed by adjuvant platinum-based chemotherapy (P-CT). However, the EORTC55971 trial suggested neoadjuvant (NACT) an alternative, showing increased optimal debulking rates and reduced surgical complications without detriment survival. CHORUS (CRUK 07/009) 2nd phase III randomized controlled investigate timing initial in OC. Methods: Patients (pts) with clinical FIGO stage III-IV OC...
<h2>Summary</h2><h3>Background</h3> Closure of an abdominal stoma, a common elective operation, is associated with frequent complications; one the commonest and impactful incisional hernia formation. We aimed to investigate whether biological mesh (collagen tissue matrix) can safely reduce incidence hernias at stoma closure site. <h3>Methods</h3> In this randomised controlled trial (ROCSS) done in 37 hospitals across three European countries (35 UK, Denmark, Netherlands), patients aged 18...
Purpose To assess long-term clinical outcomes of preoperative chemoradiotherapy magnetic resonance imaging (MRI)–defined locally advanced rectal adenocarcinoma using concurrent irinotecan and capecitabine. Patients Methods One hundred ten patients without distant metastases entered this phase II trial North West/North Wales Clinical Oncology Group (NWCOG) -2 after MRI demonstration tumor threatening (≤ 2 mm) or involving mesorectal fascia. Pelvic radiotherapy was given to 45 Gy in 25...
Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free overall survival with dose-dense weekly 3-weekly (ie, weeks) carboplatin. However, this benefit was not observed the previously results of ICON8. Here, we present final coprimary outcomes updated analyses
In colorectal cancer, epidermal growth factor receptor (EGFR) expression is reported in 8-100% of the cases examined and there has been no clear association between EGFR prognosis, or response to inhibitors. this retrospective study, 87 archival specimens from node positive (Dukes' C) cancer patients were analysed immunohistochemically, for EGFR, mutant (EGFRvIII) phosphorylated (pEGFR, tyr1068). Each section was scored on basis location intensity staining, immunostaining considered if...
Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, associated cumulative toxicity, characterised by chronic often irreversible neuropathy. To assess efficacy of 3-month versus 6-month cancer to compare health-related quality life cost-effectiveness durations. An international, randomised, open-label, non-inferiority, Phase III, parallel-group trial. A total 244...
Signalling via the insulin-like growth factor-I receptor (IGF-IR) has been associated with resistance to anti- epidermal factor (EGFR) and human receptor-2 (HER-2)-based therapies in experimental system, but coexpression clinical significance of IGF-IR, EGFR HER-2 cancer patients remains unclear. EGFR, status was assessed retrospectively tumour specimens from 87 Dukes' C colorectal using immunohistochemistry. Sections were scored by percentage positive cells (membrane cytoplasmic) intensity...
Increased expression and activation of human epidermal growth factor receptor (EGFR) HER-2 have been reported in numerous cancers. The aim this study was to determine the sensitivity a large panel ovarian cancer cell lines (OCCLs) treatment with various forms small molecule tyrosine kinase inhibitors (TKIs) cytotoxic drugs. see if there any association between protein biomarkers including three putative stem (CSC) markers (CD24, CD44, CD117/c-Kit), P-glycoprotein (P-gp), HER family members...
The prognostic role of HER-2 has been established in breast cancer but remains controversial colorectal cancer. In this study, 170 archival specimens Dukes' B and C were analysed immunohisto-chemically, using an anti-HER-2 monoclonal antibody HM64.13. Immunostaining was classified as cytoplasmic or membranous, the intensity immunostaining graded negative, weak strong. association between these scores survival estimated Cox analyses. Overall, 87% cases showed staining, with 54% exhibiting...
The human epidermal growth factor receptor (EGFR) is an important target for cancer treatment. Currently, only the EGFR antibodies cetuximab and panitumumab are approved treatment of patients with colorectal cancer. However, a major clinical challenge short-term response owing to development acquired resistance during course In this study, we investigated molecular mechanisms underlying in DiFi cells anti-EGFR mAb ICR62 (termed DiFi62) small molecule tyrosine kinase inhibitor (TKI) gefitinib...
The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic adenocarinoma threatening/involving the surgical resection plane received pelvic radiotherapy concurrent capecitabine, irinotecan and cetuximab. Resection was recommended 8 weeks later. primary endpoint histopathologically clear (R0) margin. Pre-planned...
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus usually given 6 (6 adjuvant chemotherapy in colorectal cancer. In total, 6088 patients with fully resected high-risk stage II or III cancer were followed up for 3–8 years. within-trial analysis from a UK health-care perspective presented using resource use data, quality life (EQ-5D-3L),...
Anti-EGFR mAbs cetuximab and panitumumab are routinely used for the treatment of patients with KRAS-wild type metastatic colorectal cancer (mCRC). However, in some their efficacy remains modest no clear association between EGFR protein expression determined by PharmDx™ kit, response to anti-EGFR therapies. Therefore, we investigated relative predictive value wild-type (wtEGFR), mutated EGFRvIII ligand proteins mCRC treated cetuximab. The levels wtEGFR, EGFRvIII, were immunohistochemistry...